These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8295172)

  • 21. Non-L-tryptophan related eosinophilia-myalgia syndrome with hypoproteinemia and hypoalbuminemia.
    Margolin L
    J Rheumatol; 2003 Mar; 30(3):628-9. PubMed ID: 12610828
    [No Abstract]   [Full Text] [Related]  

  • 22. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 23. [Eosinophilia myalgia syndrome, toxic oil syndrome].
    Niiyama T; Higuchi I
    Ryoikibetsu Shokogun Shirizu; 2001; (35):358-60. PubMed ID: 11555954
    [No Abstract]   [Full Text] [Related]  

  • 24. [Eosinophilia-myalgia syndrome in rheumatology].
    Nasonov EL; Shtutman VZ; Guseva NG
    Klin Med (Mosk); 1994; 72(2):17-24. PubMed ID: 8015234
    [No Abstract]   [Full Text] [Related]  

  • 25. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia-myalgia syndrome: patient status 2-4 years after onset.
    Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():19-24; discussion 24-5. PubMed ID: 8895178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Criteria for the definition of the eosinophilia-myalgia syndrome.
    Hertzman PA
    J Rheumatol Suppl; 1996 Oct; 46():7-12. PubMed ID: 8895176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know.
    Clauw DJ; Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():2-6. PubMed ID: 8895175
    [No Abstract]   [Full Text] [Related]  

  • 30. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome.
    Hisatomi A; Kubota A; Ohashi M; Umeda F; Nawata H; Imamura T; Nagata T
    Fukuoka Igaku Zasshi; 1997 Jan; 88(1):11-7. PubMed ID: 9037890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Differential diagnosis of hypereosinophilia syndrome].
    Eber B
    Dtsch Med Wochenschr; 1993 Mar; 118(12):441. PubMed ID: 8467742
    [No Abstract]   [Full Text] [Related]  

  • 33. [Neuromuscular diseases with eosinophilia].
    Pellissier JF; Figarella-Branger D; Serratrice G
    Med Trop (Mars); 1998; 58(4 Suppl):471-6. PubMed ID: 10410368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic immune activation in the eosinophilia-myalgia syndrome.
    McKinley KL; Harati Y; Schneider LW
    Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Eosinophilic myalgia syndrome].
    Vermel' AE
    Klin Med (Mosk); 1999; 77(2):4-7. PubMed ID: 10380452
    [No Abstract]   [Full Text] [Related]  

  • 36. A diagnostic algorithm for distinguishing the eosinophilia-myalgia syndrome from fibromyalgia and chronic myofascial pain.
    Taylor RM; Gabriel SE; O'Fallon WM; Bowles CA; Duffy J
    J Rheumatol Suppl; 1996 Oct; 46():13-8. PubMed ID: 8895177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome.
    Wagner KR; Elmore JG; Horwitz RI
    J Rheumatol; 1996 Dec; 23(12):2079-85. PubMed ID: 8970044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Part II. Eosinophilia-Myalgia Syndrome: further correlations between compromised histamine degradation, eosinophilias and myopathies.
    Smith MJ; Garrett RH
    Inflamm Res; 2007 Apr; 56 Suppl 1():S7-8. PubMed ID: 17806156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.